Annual Review of Medicine
Annual Review of Medicine(英文缩写 ANNU REV MED),ISSN 0066-4219,eISSN 1545-326X 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 16.048 | Q1 |
| 2022 | 10.500 | Q1 |
| 2023 | 15.100 | Q1 |
| 2024 | 22.100 | Q1 |
| 2025 | 18.800 | Q1 |
Annual Review of Medicine 最新收录文献
-
1. Treatment of Tricuspid Valve Disease.
1. 三尖瓣疾病的治疗PMID:日期:2026-10-01In the landscape of valvular heart disease, the tricuspid valve has traditionally been dubbed the forgotten valve. However, over the last several years, studies have demonstrated that tricuspid valve disease is increasing in prevalence due to a growing aging population, and tricuspid regurgitation, in particular, is associated with increased mortality and morbidity. Traditional surgical tricuspid valve replacement or repair is often an undesirable option for patients with severe tricuspid regurgitation due to the high rates of concurrent comorbidities seen in this patient population; accordingly, treatment has traditionally been largely confined to symptom management with medical therapy. More recently, however, the field has experienced a major paradigm shift toward transcatheter interventions. Pivotal trials evaluating transcatheter edge-to-edge repair and transcatheter tricuspid valve replacement have shown that these therapies safely achieve robust tricuspid regurgitation reduction, reduce heart failure hospitalization, and significantly improve patient-reported quality of life in the short term. These technologies have been key in providing treatment options for a large, previously underserved patient population, but further research is needed to establish the durability of these devices and to evaluate the cost-effectiveness of these interventions within a value-based healthcare framework.
-
2. Artificial Intelligence and Radiomics in the Diagnosis and Management of Cancer.
2. 人工智能与放射组学在癌症诊断与管理中的应用PMID:日期:2026-09-18Imaging is increasingly essential for the diagnosis, prognostication, and management of cancer patients. It is a field in rapid evolution and has the potential to provide noninvasive characterization of malignancy, which remains an important Holy Grail of medicine. Radiomics, which involves the high-throughput assessment of imaging features, aims to transform images into structured phenotypic data. By correlating imaging-derived data with clinical and molecular information, radiomics offers the potential to relate tumor biology to imaging phenotype to improve patient prognostication and management. This review surveys the principles and applications of classical and deep learning-based radiomic approaches in oncology, and it highlights key challenges in robustness and reproducibility that must be addressed to realize the potential of radiomics in clinical practice.
-
3. Spectrum of Gluten Intolerance.
PMID:日期:2026-09-17The spectrum of gluten intolerance spans celiac disease, dermatitis herpetiformis, nonceliac gluten sensitivity, and wheat allergy. These conditions share gluten as the driver perpetuating symptoms and pathology. This review seeks to compare and contrast the main conditions on the spectrum of gluten intolerance with respect to definition, epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment.
-
4. Genomic Screening for Infants and Reproductive Adults.
PMID:日期:2026-09-17Recent progress in genomic sequencing, bioinformatics, cloud computation, and artificial intelligence is advancing a more mature understanding of the architecture of childhood genetic diseases. This knowledge and these technologies are enabling expanded genomic screening of infant and reproductive adult populations. With many new disease-modifying and curative therapies in development and approval processes, there exists unparalleled opportunity to identify, treat, and decrease the population burden of genetic disease and transform medical genetics. Broad implementation of genomic population screening, however, requires investments for overcoming remaining evidence gaps and operational challenges, and for delivery in a sustainable manner that is acceptable to parents, prospective parents, and physicians.
-
5. Rethinking Complement in Homeostasis and Disease.
5. 重新思考平衡与疾病中的补体PMID:日期:2026-08-24The complement system, traditionally viewed as a central component of immune defense, is now recognized to play diverse roles in morphogenesis, tissue regeneration, cellular metabolism, and intercellular communication. This expanded perspective highlights the spatially distributed and context-dependent nature of complement activity. Consequently, our understanding of complement-mediated diseases has evolved from a model centered on excessive activation to one in which chronic inflammatory processes displace protective, complement-regulated homeostatic functions. In this review, we examine several diseases that exemplify this paradigm and discuss how this conceptual framework may inform the development of innovative therapeutic strategies aimed at restoring complement-mediated homeostasis.
-
6. Mild Autonomous Cortisol Secretion and Metabolic Syndrome: An Emerging Clinical Link.
6. 轻度自主皮质醇分泌与代谢综合征：一个新出现的临床关联PMID:日期:2026-08-20Adrenal incidentalomas are increasingly encountered in routine clinical practice, driven by widespread imaging use and rising cardiometabolic disease burden. Mild autonomous cortisol secretion (MACS), characterized by low-grade, adrenocorticotropic hormone-independent cortisol excess in the absence of overt Cushingoid features, is the most common functional phenotype. Across observational cohorts, MACS is associated with a higher burden of hypertension, dysglycemia, dyslipidemia, obesity, and fractures; importantly, risk increases continuously with rising post-dexamethasone suppression test (DST) cortisol levels, including values traditionally categorized as nonfunctioning. Diagnosis centers on the 1-mg overnight DST, interpreted in clinical context and with careful attention to common interferents. The limitations of cortisol thresholds alone have prompted interest in adjunctive hormonal markers and composite clinical-biochemical risk stratification. Management is individualized, ranging from optimized cardiometabolic therapy to adrenalectomy in selected patients with clinically relevant comorbidities, while medical cortisol-modulating therapies remain investigational. This review synthesizes current evidence on the diagnosis, cardiometabolic implications, and management of MACS; highlights key uncertainties; and outlines future directions aimed at improving risk stratification and informing clinical decision-making for this increasingly prevalent condition.
-
7. Food is Medicine Interventions to Improve Health.
7. 食物是改善健康的药物干预措施PMID:日期:2026-08-14Barriers to healthy eating lead to substantial health harms, but clinicians have historically had few tools to help patients address them. To fill this gap, food is medicine (FIM) interventions seek to improve the prevention or management of specific clinical conditions through the provision of healthy food resources and other strategies to address barriers to healthy eating. This article describes the rationale for and major types of FIM and reviews key studies and developments in the field. We note that the evidence to date shows promising benefits for FIM, including for both clinical outcomes and health care utilization, but it also has meaningful limitations and unexpected findings. We discuss results from evaluations of large-scale FIM implementation, particularly in Medicaid, and why FIM studies may have been more or less effective in different contexts. We conclude with several implementation learnings that can guide researchers going forward.
-
8. Novel Antibodies for Managing Cachexia.
8. 用于管理恶病质的新型抗体PMID:日期:2026-08-04[中文摘要] 恶病质是一种复杂的多因素综合征，由厌食和全身性炎症驱动，最终导致以体重下降、肌肉量减少和身体功能受损为特征的分解代谢状态。许多慢性合并症参与恶病质的病理生理过程，其中恶性肿瘤是最常见的合并症之一。尽管迄今为止获批的针对恶病质的疗法有限，但生长分化因子15（GDF-15）-胶质细胞源性神经营养因子家族受体α样（GFRAL）信号轴已被确定为恶病质的主要介质，是恶病质靶向治疗和抗体研发中一个值得关注的通路。Ponsegromab是一种单克隆抗体，为高选择性、强效的GDF-15抑制剂，已在癌症患者中改善体重及其他恶病质相关症状。其他抗GDF-15和抗GFRAL疗法目前正在研究中。通过这些疗法的开发，已发现许多意想不到的潜在治疗应用，凸显了恶病质广泛的全身性影响。随着研究的继续，必须重点关注明确的试验设计和终点指标。
[英文摘要] Cachexia is a complex, multifactorial syndrome driven by anorexia and systemic inflammation, ultimately resulting in a catabolic state characterized by weight loss, decreased muscle mass, and impaired physical function. Many chronic comorbidities are implicated in the pathophysiology of cachexia, with malignancy being one of the most common. Although approved cachexia-directed therapies are limited to date, the growth differentiation factor 15 (GDF-15)-glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) signaling axis has been identified as a primary mediator of cachexia and is an interesting pathway for cachexia-directed therapies and antibodies. Ponsegromab, a monoclonal antibody that is a highly selective and potent inhibitor of GDF-15, has resulted in improved body weight and other cachexia-related symptoms in patients with cancer. Other anti-GDF-15 and anti-GFRAL therapies are currently under investigation. Through the development of these treatments, many unexpected potential therapeutic applications have been identified, highlighting the broad, systemic impacts of cachexia. As research continues, it is imperative to focus on clear trial design and endpoints.
-
9. Advances in Approaches to Managing Esophageal Adenocarcinoma.
PMID:日期:2026-07-27Management of esophageal adenocarcinoma is moving toward personalized, multimodal approaches, with perioperative immunotherapy now a key component. Shortly before 2025, perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy was established as superior to neoadjuvant chemoradiotherapy, significantly improving overall survival by better controlling micrometastatic disease. Recent US Food and Drug Administration and European Medical Agency approvals of perioperative durvalumab adds immunotherapy to FLOT. Organ-preserving "watch-and-wait" strategies are gaining momentum for clinical complete responders to avoid surgery-related morbidity. We highlight landmark studies that inform use of different modern multimodal approaches. These advances, combined with robot-assisted surgery, are collectively improving 5-year survival for localized disease.
-
10. APOL1-Mediated Kidney Disease and the Emerging Era of Precision Therapy.
PMID:日期:2026-07-21renal risk genetic variants (G1 and G2) account for a substantial portion of the excess burden of nondiabetic kidney disease among individuals with recent African ancestry (within the past 10,000 years). Apolipoprotein L1 (APOL1)-mediated kidney disease is characterized by incomplete penetrance and appears to require inflammatory or environmental "second hits" that increase APOL1 expression, activating toxic function in kidney cells. Mechanistic studies support a model in which APOL1 channel activity, intracellular trafficking stress, mitochondrial dysfunction, and inflammasome signaling contribute to podocyte and glomerular injury. These insights have made APOL1 an ideal target for precision nephrology. Emerging therapeutic strategies include direct APOL1 channel blockade, inhibition of Janus kinase (JAK)-signal transducer and activator of transcription protein (STAT)-dependent APOL1 induction, antisense oligonucleotides that lower APOL1 expression, and downstream anti-inflammatory approaches. The major translational questions are who should be tested, who should be treated, and how to balance kidney benefit with host-defense, equity, and implementation challenges.